tiprankstipranks
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
US Market
FDMT
4D Molecular Therapeutics
RESEARCH TOOLSreports
Want to see FDMT full AI Analyst Report?

4D Molecular Therapeutics (FDMT) Stock Forecast & Price Target

528 Followers
See the Price Targets and Ratings of:

FDMT Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
4D
Molecular Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FDMT Stock 12 Month Forecast

Average Price Target

$32.80
▲(225.72% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for 4D Molecular Therapeutics in the last 3 months. The average price target is $32.80 with a high forecast of $37.00 and a low forecast of $23.00. The average price target represents a 225.72% change from the last price of $10.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","38":"$38","13.25":"$13.25","21.5":"$21.5","29.75":"$29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.25,21.5,29.75,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.18,12.243076923076924,14.306153846153846,16.369230769230768,18.432307692307692,20.495384615384616,22.558461538461536,24.62153846153846,26.684615384615384,28.747692307692308,30.810769230769232,32.87384615384615,34.93692307692308,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.18,11.92,13.66,15.399999999999999,17.14,18.88,20.619999999999997,22.36,24.099999999999998,25.839999999999996,27.58,29.319999999999997,31.059999999999995,{"y":32.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.18,11.166153846153845,12.152307692307692,13.138461538461538,14.124615384615385,15.11076923076923,16.096923076923076,17.083076923076923,18.06923076923077,19.055384615384614,20.04153846153846,21.027692307692305,22.013846153846153,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.18,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$37.00Average Price Target$32.80Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on FDMT
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)
Bank of America Securities Analyst forecast on FDMT
Daniel Giraldo
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Alto Neuroscience, Inc. (NYSE: ANRO) and Irhythm Technologies (NASDAQ: IRTC)
H.C. Wainwright Analyst forecast on FDMT
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$36
Buy
257.50%
Upside
Reiterated
08/14/26
Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials
Morgan Stanley Analyst forecast on FDMT
Judah Frommer
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (NASDAQ: DWTX), Talphera (NASDAQ: TLPH) and 4D Molecular Therapeutics (NASDAQ: FDMT)
RBC Capital Analyst forecast on FDMT
Lisa Walter
RBC Capital
RBC Capital
$35
Buy
247.57%
Upside
Reiterated
08/14/26
RBC Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)
B. Riley Securities Analyst forecast on FDMT
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$37
Buy
267.43%
Upside
Initiated
07/31/26
4D Molecular Therapeutics (FDMT) Receives a Buy from B. Riley Securities
Goldman Sachs Analyst forecast on FDMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$33
Buy
227.71%
Upside
Reiterated
07/20/26
Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)
Evercore ISI Analyst forecast on FDMT
Jonathan Miller
Evercore ISI
Evercore ISI
$23
Buy
128.40%
Upside
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS) and 4D Molecular Therapeutics (NASDAQ: FDMT)
Chardan Capital Analyst forecast on FDMT
Geulah Livshits
Chardan Capital
Chardan Capital
$26
Buy
158.19%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Rockwell Med (NASDAQ: RMTI), 4D Molecular Therapeutics (NASDAQ: FDMT) and Cognition Therapeutics (NASDAQ: CGTX)
Jefferies Analyst forecast on FDMT
Faisal Khurshid
Jefferies
Jefferies
$40→$21
Buy
108.54%
Upside
Initiated
03/30/26
4D Molecular assumed with a Buy at Jefferies4D Molecular assumed with a Buy at Jefferies
Barclays Analyst forecast on FDMT
Eliana Merle
Barclays
Barclays
$33
Buy
227.71%
Upside
Reiterated
01/27/26
4D Molecular assumed with an Overweight at Barclays4D Molecular assumed with an Overweight at Barclays
Leerink Partners Analyst forecast on FDMT
Mani Foroohar
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
10/15/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Cantor Fitzgerald Analyst forecast on FDMT
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)
Bank of America Securities Analyst forecast on FDMT
Daniel Giraldo
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT), Alto Neuroscience, Inc. (NYSE: ANRO) and Irhythm Technologies (NASDAQ: IRTC)
H.C. Wainwright Analyst forecast on FDMT
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$36
Buy
257.50%
Upside
Reiterated
08/14/26
Analyst Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target as 4D-150 Advances Through Late-Stage Trials
Morgan Stanley Analyst forecast on FDMT
Judah Frommer
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (NASDAQ: DWTX), Talphera (NASDAQ: TLPH) and 4D Molecular Therapeutics (NASDAQ: FDMT)
RBC Capital Analyst forecast on FDMT
Lisa Walter
RBC Capital
RBC Capital
$35
Buy
247.57%
Upside
Reiterated
08/14/26
RBC Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)
B. Riley Securities Analyst forecast on FDMT
Unknown Analyst
B. Riley Securities
Not Ranked
B. Riley Securities
$37
Buy
267.43%
Upside
Initiated
07/31/26
4D Molecular Therapeutics (FDMT) Receives a Buy from B. Riley Securities
Goldman Sachs Analyst forecast on FDMT
Salveen Richter
Goldman Sachs
Goldman Sachs
$33
Buy
227.71%
Upside
Reiterated
07/20/26
Analysts' Top Healthcare Picks: Novartis (NVS), 4D Molecular Therapeutics (FDMT)
Evercore ISI Analyst forecast on FDMT
Jonathan Miller
Evercore ISI
Evercore ISI
$23
Buy
128.40%
Upside
Reiterated
07/20/26
Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS) and 4D Molecular Therapeutics (NASDAQ: FDMT)
Chardan Capital Analyst forecast on FDMT
Geulah Livshits
Chardan Capital
Chardan Capital
$26
Buy
158.19%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Rockwell Med (NASDAQ: RMTI), 4D Molecular Therapeutics (NASDAQ: FDMT) and Cognition Therapeutics (NASDAQ: CGTX)
Jefferies Analyst forecast on FDMT
Faisal Khurshid
Jefferies
Jefferies
$40→$21
Buy
108.54%
Upside
Initiated
03/30/26
4D Molecular assumed with a Buy at Jefferies4D Molecular assumed with a Buy at Jefferies
Barclays Analyst forecast on FDMT
Eliana Merle
Barclays
Barclays
$33
Buy
227.71%
Upside
Reiterated
01/27/26
4D Molecular assumed with an Overweight at Barclays4D Molecular assumed with an Overweight at Barclays
Leerink Partners Analyst forecast on FDMT
Mani Foroohar
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
10/15/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 4D Molecular Therapeutics

3 Months
Daniel GiraldoBank of America Securities
Success Rate
8/14 ratings generated profit
57%
Average Return
+17.40%
Copying Daniel Giraldo's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +17.40% per trade.
1 Year
Daniel GiraldoBank of America Securities
Success Rate
14/14 ratings generated profit
100%
Average Return
+53.38%
Copying Daniel Giraldo's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.38% per trade.
2 Years
Daniel GiraldoBank of America Securities
Success Rate
14/14 ratings generated profit
100%
Average Return
+79.11%
Copying Daniel Giraldo's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FDMT Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
11
7
11
8
Buy
0
0
0
0
1
Hold
2
2
1
1
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
13
8
12
12
In the current month, FDMT has received 9 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. FDMT average Analyst price target in the past 3 months is 32.80.
Each month's total comprises the sum of three months' worth of ratings.

FDMT Financial Forecast

FDMT Earnings Forecast

Next quarter’s earnings estimate for FDMT is -$1.04 with a range of -$1.09 to -$0.99. The previous quarter’s EPS was -$1.04. FDMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.
Next quarter’s earnings estimate for FDMT is -$1.04 with a range of -$1.09 to -$0.99. The previous quarter’s EPS was -$1.04. FDMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.

FDMT Sales Forecast

Next quarter’s sales forecast for FDMT is $3.61M with a range of $0.00 to $5.60M. The previous quarter’s sales results were $3.78M. FDMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.
Next quarter’s sales forecast for FDMT is $3.61M with a range of $0.00 to $5.60M. The previous quarter’s sales results were $3.78M. FDMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FDMT has Performed in-line its overall industry.

FDMT Stock Forecast FAQ

What is FDMT’s average 12-month price target, according to analysts?
Based on analyst ratings, 4D Molecular Therapeutics’s 12-month average price target is 32.80.
    What is FDMT’s upside potential, based on the analysts’ average price target?
    4D Molecular Therapeutics has 225.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FDMT a Buy, Sell or Hold?
          4D Molecular Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is 4D Molecular Therapeutics’s price target?
            The average price target for 4D Molecular Therapeutics is 32.80. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $37.00 ,the lowest forecast is $23.00. The average price target represents 225.72% Increase from the current price of $10.07.
              What do analysts say about 4D Molecular Therapeutics?
              4D Molecular Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of FDMT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.